EAM
CYTK icon

Eagle Asset Management’s Cytokinetics CYTK Stock Holding History

Eagle Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-195,449
Closed -$14.3M – 568
2024
Q1 		$14.3M Sell
195,449
-8,098
-4% -$626K 0.07% 235
2023
Q4 		$17M Sell
203,547
-193,223
-49% -$7M 0.09% 205
2023
Q3 		$11.7M Sell
396,770
-7,392
-2% -$246K 0.07% 234
2023
Q2 		$13.2M Sell
404,162
-96,223
-19% -$3.56M 0.07% 225
2023
Q1 		$17.6M Sell
500,385
-47,692
-9% -$1.95M 0.1% 179
2022
Q4 		$24.3M Sell
548,077
-10,673
-2% -$459K 0.15% 153
2022
Q3 		$27.1M Buy
558,750
+127,327
+30% +$6.13M 0.18% 146
2022
Q2 		$16.9M Buy
431,423
+196,878
+84% +$7.93M 0.11% 189
2022
Q1 		$8.63M Buy
+234,545
New +$8.33M 0.04% 298

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eagle Asset Management's CYTK Position: Q2 2024 in Review

Eagle Asset Management sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 195,449 shares — an estimated $14.3M sold.

Eagle Asset Management first reported a position in CYTK in Q1 2022 and held it in 9 quarters. The position peaked at $27.1M in Q3 2022. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Eagle Asset Management reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Eagle Asset Management sold 195,449 Cytokinetics shares in Q2 2024, an estimated $14.3M.
  • Eagle Asset Management first reported a position in Cytokinetics in Q1 2022 and held it in 9 quarters.
  • Eagle Asset Management's Cytokinetics position peaked at $27.1M in Q3 2022.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Eagle Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.